Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06741228 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
A Phase 3 study of Generalized Anxiety Disorder, sponsored by Definium Therapeutics US.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06741228 is a Phase 3 study of Generalized Anxiety Disorder that is actively recruiting participants, run by Definium Therapeutics US. The registered enrollment target is 200 participants, roughly in line with the 211-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target. The trial reports 20 study locations across 10 states.
The verdict
NCT06741228, a Phase 3 study of Generalized Anxiety Disorder, is actively recruiting participants, sponsored by Definium Therapeutics US.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Conditions Studied
Interventions
- OTHER Placebo
- DRUG MM120 (LSD D-Tartrate)
Study Locations (20)
California
- Kadima Neuropsychiatry Institute - La Jolla
- UCSF Department of Neurology - San Francisco
- Psychedelic Science Institute - Santa Monica
Florida
- Clinical Neuroscience Solutions Inc. - Jacksonville
- Accel Research Sites - Lakeland CRU - Lakeland
- Segal Trials - Lauderhill
Georgia
- Atlanta Center for Medical Research - Atlanta
- iResearch Atlanta - Decatur
- CenExel iResearch, LLC - Savannah
New York
- Spectrum Neuroscience and Treatment Institute - New York
- Adams Clinical Harlem - New York
- New York State Psychiatric Institute (NYSPI) - New York
Arizona
- Lighthouse Psychiatry - Gilbert
- Scottsdale Research Institute - Scottsdale
Massachusetts
- Adams Clinical Boston - Boston
- Adams Clinical Watertown - Watertown
Colorado
- Mountain View - Denver
Illinois
- Uptown Research Institute - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06741228
The ClinicalTrials.gov registry entry for NCT06741228 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 211-participant average among 48 other Generalized Anxiety Disorder trials with a reported enrollment target. The listed sponsor is Definium Therapeutics US, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Generalized Anxiety Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06741228 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06741228 about?
NCT06741228 is a clinical study titled "A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)". A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
What is the current status of trial NCT06741228?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2024-12-11. Estimated completion is 2026-11.
What conditions does trial NCT06741228 study?
This clinical trial studies the following conditions: Generalized Anxiety Disorder.
What interventions are being tested in trial NCT06741228?
The interventions under investigation include: Placebo (OTHER), MM120 (LSD D-Tartrate) (DRUG).
Who is sponsoring clinical trial NCT06741228?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06741228 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Generalized Anxiety Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama)
RECRUITING · Phase 3
-
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Long Term Chamomile Therapy for Anxiety
COMPLETED · Phase 3
-
Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder
COMPLETED · Phase 3
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
-
Neurofeedback Enhanced Cognitive Reappraisal Training - Phase 4
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.